A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever.The newly app ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

Experts said millions of people across the country are prescribed a medicine for moderate to severe acute pain each year, so ...

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

Journavx is the first new type of pain reliever approved by the FDA to hit the market in more than two decades. Emory ...

The FDA has approved the first new type of pain medication in more than two decades — and it’s not an opioid. The drug is Suzetrigine under the brand name Journavx. It is now FDA-approved to treat ...